Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914589 · ClinicalTrials.gov registry record · Phase 2
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 479
- Enrollment target
NCT00914589: Completed Phase 2 study, sponsored by Novo Nordisk A/S.
NCT00914589 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 479 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (260% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00914589, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 479 participants
- Enrollment target
Study Summary
This trial is conducted in Canada, Asia, Europe and USA. The aim of this clinical trial is to investigate the effect and safety of rFXIII on transfusion needs in patients undergoing heart surgery.
Primary Outcome
Proportion of patients avoiding blood products given via allogeneic transfusion. Blood products were defined as any of the following: RBC, platelets, FFP, fibrinogen concentrate and clotting factor(s) concentrate, including cryoprecipitate.
Interventions
- DRUG placebo
- DRUG catridecacog
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
What the finished NCT00914589 record still lists
NCT00914589 is an interventional study that assigns participants to a tested intervention. The registered 479 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (260% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00914589 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00914589 about?
NCT00914589 is a clinical study titled "Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery". This trial is conducted in Canada, Asia, Europe and USA. The aim of this clinical trial is to investigate the effect and safety of rFXIII on transfusion needs in patients undergoing heart surgery.
What is the current status of trial NCT00914589?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 479 participants. The study started on 2009-07. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00914589?
The interventions under investigation include: placebo (DRUG), catridecacog (DRUG).
Who is sponsoring clinical trial NCT00914589?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00914589's enrollment target sits among peer trials
479 77th of 2000 higher than 1,924 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04221542 · 479 participants · Phase 1
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia